Boston Scientific's Farapoint PFA Catheter Receives FDA Approval, Expanding Farapulse Platform for Atrial Fibrillation and Flutter Treatment
Farapulse
Atrial Fibrillation Treatment Catheter Tool Manufacturer
On January 13, 2026, Boston Scientific (NYSE: BSX) announced that itsFarapulse Pulsed Field Ablation (PFA) CatheterHas received FDA approval in the United States. This information was disclosed by Nick Spadea-Anello, Senior Vice President and President of the company's electrophysiology business, on the LinkedIn platform.
The FDA approval came less than two months after the product received CE certification., marking the official entry of Farapoint into the two core regulatory market systems of Europe and the United States, forFarapulse The platform adds a new tool, providing electrophysiologists with a PFA solution equipped with navigation capabilities——A single catheter can simultaneously create point and linear ablation lesions.。
# Registration and Indications Scope
According to the disclosure, the Farapoint PFA Catheter, as a component of the Farapulse PFA System, has been approved for the following scenarios:
As an auxiliary catheter for the Farawave PFA catheter;
In the treatment of drug-refractory, symptomatic persistent atrial fibrillation (persistent AFib);
For cardiac useTricuspid ValveIsthmus (CTI, cavotricuspid isthmus) regionAblation.
The approved positioning is "adjunctive catheter," which serves to provide supplementary ablation functionality within the existing PFA treatment process.
Farapoint+ Farapulse Will provide a brand-new "one-stop" solution for atrial flutter and atrial fibrillation, and clinical studies have also confirmed the effectiveness and safety of this combination. Moreover, it significantly improves operational predictability and shortens the overall procedure time compared to radiofrequency ablation. Demonstrating...Farapoint+FarapulseThe Advantages of Combination Therapy for Atrial Flutter and Atrial Fibrillation.
# Product Categories and Application Scenarios
Farapoint belongs to the pulsed field ablation (PFA) catheter product category, targeting atrial fibrillation treatment scenarios in the electrophysiology interventional field. As a rapidly developing ablation technology in recent years, PFA is becoming an important technical branch beyond radiofrequency and cryoablation due to its selectivity for myocardial tissue and minimal damage to surrounding structures.
In clinical applications, Farapoint mainly serves:
Linear Ablation and Focal Ablation: Supplementary Procedures;
Ablation requirements for special anatomical structures such as the CTI region;
Used in combination with the Farawave main ablation catheter.
# Key Features of Products and Systems
According to Boston Scientific, the core features of Farapoint include:
The Same Catheter Supports Both Focal and Linear Ablation Patterns
Can flexibly form different shapes of ablation lines in different anatomical structures.Support Navigation System Integration (Nav-Enabled)
Enhance the positioning and path control capabilities in electrophysiological procedures.System-Level Collaborative Visualization
Farapoint and Faraview Imaging Systems, when used together on the Opal HDx Mapping Platform, enhance the visualization of catheter positioning and lesion formation to support more controlled PFA energy delivery.
Overall, Farapoint is not an independent system product but is laid out as an important functional module within the Farapulse PFA System.
# Relevant Clinical Data
Farapoint Fast Approval Thanks to Phase II Data from the ADVANTAGE Atrial Fibrillation Clinical TrialSupport, confirming the Farapulse PFA platform andFarapoint Catheter for Persistent Atrial Fibrillation andRight Atrial FlutterThe Effectiveness and Safety of Adjuvant Therapy.
The study found that those who receivedFarapointAmong the 141 patients who underwent PFA catheter CTI ablation, 80 cases wereRight Atrial FlutterHistory of patients, 17 cases occurred during surgeryRight Atrial Flutter, 44 cases were based on patient preference.
The average number of PFA discharges for CTI during the operation was 18±6 times, and immediate bidirectional CTI block was achieved in 98.6% (139/141 cases) of patients. The average ablation time for CTI was 8±13 minutes. The intraoperative nitroglycerin regimen included an initial bolus dose of 3mg, followed by an additional 2mg bolus dose; however, most patients only received the initial 3mg bolus. The prophylactic use of nitroglycerin during CTI ablation completely prevented the occurrence of coronary artery spasm.
Postoperative follow-up results showed that this subgroup cohort achieved all efficacy and safety endpoints: 97.9% did not experienceRight Atrial FlutterRecurrence, with the first phase of this trialThe effective rate of 98% for intraoperative radiofrequency ablation (standard therapy) is comparable; at the same time,FarapointThe safety indicators of the PFA catheter group were similar to those of the radiofrequency ablation group (the incidence of adverse events at 90 days post-operation was 2.1% vs 2.0%, respectively). Subgroup analysis also showed that, compared with radiofrequency ablation,Farapoint In CTI ablation applications, it significantly enhanced operational predictability and reduced overall procedure time. These findings indicate higher reliability in practical use, leading to more consistent workflow and procedural efficiency.
# BSCI Star ProductsFarapulse System
As the most researched and utilized globallyPFASystem, Boston ScientificFarapulse The system has treated more than710,000 patients.
2025Year2Month5On the same day, Boston Scientific announced2024Q4 and full-year results for the year. Among them,Electrophysiology Business Q4 Sales Were6.49Billion US dollars, with total annual sales of19Billion US dollars, respectively increasing by nearly171%And138%。
The financial report states that, in2024Obtained at the beginning of the yearFDA After approval,Farapulse System to2024Sales at the end of the yearExceed10Billion US dollars. The company's leadership had previouslyFarapulse SystemDescribed as the most transformative product in Boston Scientific's history. Since its commercial launch, it has driven the growth of electrophysiology sales, including2024 Year-on-year growth in the first quarter70%, the second quarter125% And the third quarter's177%。
Chairman and CEO of Boston ScientificCEO Mike MahoneySay,"2024This year has been one of the best in Boston Scientific's history, driven by our innovative product portfolio, the launch of the Farapulse system, and clinical and commercial breakthroughs across businesses and regions. We have laid a strong foundation for growth and will continue to transform the lives of millions of patients worldwide."
FarapulseSystem Composition
Besides the Farapoint catheter,The Farapulse system is composed ofComposed of the FARAWAVE Single-Use Cardiac Pulsed Field Ablation Catheter, FARASTAR Pulsed Field Ablation System, and FARADRIVE Single-Use Steerable Sheath.
FARADRIVE：Is a13FrA distal deflectable sheath that can betterFARAWAVENavigate to the vestibules of various pulmonary veins。
FARAWAVE：It is a diameter of12FrThe ablation catheter, whose distal end adopts a uniquePetal-shapedDesign, with a total of5"petals," each "petal" is equipped with4ElectrodeThe slider button on the handle can be used to control whether the distal end is in the "bud" or "full bloom" state. When5Each "petal" fully opens to form a flat petal shape. If partially expanded, it forms a three-dimensional basket shape. The basket diameter can be adjusted via catheter expansion and contraction.FARAWAVEThere is2Model Specifications（FARAWAVEAndFARAWAVE NAV），TheyThe biggest difference is thatMaximum diameter when the "flower" is in full bloom，The maximum diameter of this product is respectively31mmAnd35mm。
FARASTAR：Using bipolar and biphasic waveforms as well as proprietary pulses. The interface is simple to operate, just through3A single button can achieve pulmonary vein vestibule isolation.
Innovative Advantages
Multi-level Pulsed Electric Field Ablation:Possess1800V、1900V、2000VThree voltage parameter options, high tissue selectivity, reduced damage to adjacent tissues, and rapid formation of durable ablation lesions.
Unique“Petal”Structural Catheter:FARAWAVEThe petal design of the catheter can be adjusted to a basket shape or petal shape, adapting to different pulmonary vein morphologies, improving electrode contact with myocardial tissue, and enhancing surgical efficiency.
Standardized Ablation Procedure:Using a combination of basket-shaped and petal-shaped ablation with a rotating catheter to improve surgical flow and efficiency。
Shorter learning curve:The interface is easy to operate, with a stable catheter tip designed for guidewire guidance, and efficient energy delivery reduces operational difficulty, shortening the doctor's learning curve.
# Regulatory and Market Background
The main body of the Farapulse PFA System received FDA approval in 2024, marking it as one of Boston Scientific's key strategic products in the field of atrial fibrillation ablation. The approval of Farapoint is seen as a further enhancement to the system’s clinical toolset.
In the current global electrophysiology market:
PFA technology is in the stage of accelerated commercialization;
Major vendors are pursuing differentiated strategies around various anatomical approaches, ablation patterns, and system synergies.
Multi-catheter combined platform architecture has gradually become one of the mainstream directions for system evolution.
The approval of Farapoint has further enhanced Boston Scientific's product portfolio at the PFA catheter toolchain level.
# Position in Boston Scientific's Overall Layout
At the corporate planning level, Boston Scientific has clearly stated:
Farapoint is expected to launch commercialization and enter the market within 2026.
The first round of market launch will be in the EMEA region;
The Farapulse system will subsequently launch the Faraflex product (a catheter with both mapping and PFA functions), which is currently still in the clinical trial stage.
In terms of product timelines, Farapoint is a modular product that has entered the late stage of registration and is about to be commercialized, while Faraflex is part of the mid- to long-term product pipeline.
Boston Scientific stated that Farapoint, together with Farawave, Faraview, and the Opal HDx mapping system, forms an important part of its electrophysiology PFA platform architecture, serving its systematic competitive strategy in the electrophysiology field.
# Heart Future · Observation
From the perspective of registration progress and product positioning, Farapoint is not a single breakthrough product but a key complementary tool in Boston Scientific's efforts to build a PFA system platform. Its FDA approval signifies that the company is gradually evolving from a single-catheter solution to a multi-module collaborative system in the PFA treatment pathway for atrial fibrillation.
Against the backdrop of PFA technology still being in a rapid clinical penetration phase, functionally specific catheters like Farapoint are expected to play an increasingly important role in the standardization of clinical workflows and system differentiation competition.
GCC2025
Full Disease Solution for Cardiovascular Devices
Statement
Content Declaration:"Future of the Heart" tracks global medical technology advancements, aiming to disseminate technical and industrial knowledge. All content is intended for industry exchange and academic discussion, and does not constitute medical advice or commercial promotion. Information about companies, products, and registration mentioned in the text is sourced from publicly available materials or verified channels. If there are any errors or omissions, please contact us for corrections. Email: jacky@suribot.com
Copyright Statement:The original article "Heart of the Future" is owned by Beijing Siyu Bot Technology Co., Ltd. Unauthorized reproduction, excerpting, or mirroring on other websites, official accounts, or commercial platforms is prohibited; for authorized reproduction, please contact the backend to obtain permission. This platform reserves the right to pursue legal responsibility for unauthorized full-text reproduction, rewriting, or paraphrasing.
